Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertriglyceridemia: HELP
Articles from Mount Sinai Hospital New York
Based on 9 articles published since 2010
||||

These are the 9 published articles about Hypertriglyceridemia that originated from Mount Sinai Hospital New York during 2010-2020.
 
+ Citations + Abstracts
1 Review Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. 2018

Rawla, Prashanth / Sunkara, Tagore / Thandra, Krishna Chaitanya / Gaduputi, Vinaya. ·Department of Internal Medicine/Hospitalist, SOVAH Health, 320 Hospital Dr, Martinsville, VA, 24115, USA. rawlap@gmail.com. · Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of the Mount Sinai Hospital, New York, NY, 11201, USA. · Department of Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Division of Gastroenterology, SBH Health System, Bronx, NY, 19457, USA. ·Clin J Gastroenterol · Pubmed #29923163.

ABSTRACT: Hypertriglyceridemia (HTG) is an uncommon but well-established cause of acute pancreatitis (AP) comprising up to 7% of the cases. The clinical course of HTG-induced pancreatitis (HTGP) is highly similar to that of AP of other etiologies with HTG being the only distinguishing clinical feature. However, HTGP is often correlated with higher severity and elevated complication rate. At present, no approved treatment guideline for the management of HTGP is available, although different treatment modalities such as insulin, heparin, fibric acids, and omega 3 fatty acids have been successfully implemented to reduce serum triglycerides (TG). Plasmapheresis has also been used to counteract elevated TG levels in HTGP patients. However, it has been associated with complications. Following the management of acute phase, lifestyle modifications including dietary adjustments and drug therapy are essential in the long-term management of HTGP and the prevention of its relapse. Results from studies of small patient groups describing treatment and prevention of HTGP are not sufficient to draw solid conclusions resulting in no treatment algorithm being available for effective management of HTGP. Therefore, prospective randomized, active-controlled clinical studies are required to find a better treatment regimen for the management of HTGP. Until date, one randomized clinical trial has been performed to compare clinical outcomes of different treatment approaches for HTGP. However, further studies are required to outline a generalized and efficient treatment regimen for the management of HTGP.

2 Review Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. 2017

Shoar, Saeed / Saber, Alan A. ·Department of Metabolic and Bariatric Surgery, The Brooklyn Hospital Center, Icahn School of Medicine at Mount Sinai, Brooklyn, NY. Electronic address: saber6231@gmail.com. · Department of Metabolic and Bariatric Surgery, The Brooklyn Hospital Center, Icahn School of Medicine at Mount Sinai, Brooklyn, NY. ·Surg Obes Relat Dis · Pubmed #27720197.

ABSTRACT: OBJECTIVE: This study aimed to compare midterm and long-term weight loss and resolution of co-morbidity with laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG). SUMMARY: LRYGB and LSG are the most common procedures performed in bariatric surgery. However, their weight loss efficacy in the midterm and long-term has not been well compared. METHODS: A meta-analysis was performed by systematically identifying comparative studies conducted until the end of June 2016 that investigated weight loss outcome and resolution of co-morbidities (type 2 diabetes mellitus, hypertension, hyperlipidemia, hypertriglyceridemia, and obstructive sleep apnea) with LRYGB and LSG in the midterm (3-5 years) and long term (≥5 years). The primary endpoint was weight loss after LRYGB versus LSG. The secondary endpoint was resolution of co-morbidities after these procedures. RESULTS: Fourteen studies comprising 5264 patients were eligible. Follow-up ranged from 36 months to 75.8±8.4 months. The pooled result for weight loss outcomes did not show any significant difference in midterm weight loss (standardized mean difference = -0.03; 95% confidence interval (CI), -0.38-.33; P = .88) but a significant difference in the long-term weight loss outcome favoring LRYGB (standardized mean difference = .17; 95% CI, .05-.28; P= .005). The pooled results demonstrated no significant difference for resolution of type 2 diabetes mellitus, hypertension, hyperlipidemia, and hypertriglyceridemia. CONCLUSION: Despite the insignificant difference between LRYGB and LSG in midterm weight loss, LRYGB produced better weight loss in the long-term. There was no significant difference between the 2 procedures for co-morbidity resolution.

3 Review An unusual presentation of eruptive xanthoma: A case report and literature review. 2016

Kashif, Muhammad / Kumar, Hanesh / Khaja, Misbahuddin. ·aDivision of Pulmonary and Critical Care Medicine bDepartment of Medicine, Bronx Lebanon Hospital Center, Affiliated with Icahn School of Medicine at Mount Sinai, NY, USA. ·Medicine (Baltimore) · Pubmed #27631252.

ABSTRACT: BACKGROUND: Eruptive xanthomas are benign skin lesions caused by localized deposition of lipids in the dermis. The lesions are generally caused by elevated levels of serum triglycerides that leak through the capillaries and are phagocytosed by macrophages in the dermis. Clinical manifestation varies from asymptomatic skin lesions to intense pruritus and tenderness. METHODS: We present a case of a middle-aged man admitted with diabetic ketoacidosis secondary to noncompliance with insulin. He was found to have skin lesions as multiple crusted papules on the extremities. Further evaluation revealed elevated serum triglycerides. A diagnosis of eruptive xanthomas was made on skin biopsy, and after starting treatment with lipid lowering agents his cutaneous lesions gradually subsided. CONCLUSION: Appearance of eruptive xanthomas can signify the onset of serious complications. Prompt recognition of such skin manifestations is warranted to prevent development of fatal medical condition like coronary artery disease and pancreatitis.

4 Review Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. 2014

Rosenson, Robert S / Davidson, Michael H / Hirsh, Benjamin J / Kathiresan, Sekar / Gaudet, Daniel. ·Mount Sinai Heart, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu. · Division of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, Illinois. · Mount Sinai Heart, Mount Sinai Hospital, New York, New York. · Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. · ECOGENE-21 and Lipid Clinic, Department of Medicine, Université de Montreal, Chicoutimi, Quebec, Canada. ·J Am Coll Cardiol · Pubmed #25500239.

ABSTRACT: Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.

5 Clinical Trial Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. 2010

Rosenson, Robert S / Helenowski, Irene B / Tangney, Christine C. ·Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1070, New York, NY 10017, USA. robert.rosenson@mssm.edu ·Cardiovasc Drugs Ther · Pubmed #20922563.

ABSTRACT: BACKGROUND: Hypertriglyceridemia subjects with metabolic syndrome exhibit variable postprandial triglyceride responses. We investigate the effects of fenofibrate therapy on postprandial triglyceride-containing lipoproteins in subjects with early (3.5 h) versus late (8 h) postprandial triglyceride responses. METHODS: Fifty-five subjects with fasting hypertriglyceridemia (≥1.7 mmol/L (150 mg/ dL) and <5.8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial. A standardized fat load (50 g/m(2)) was given orally after a 12 h fast. Blood specimens were obtained at 0 h (fasting), 3.5 h, and 8 h after the test meal. Analysis is confined to the 53 subjects with clearly identifiable early or late triglyceride peaks prior to therapy. RESULTS: Fenofibrate was more effective in late peakers (n = 8) when compared to early peakers (n = 15) with respect to reducing postprandial triglyceride concentrations (-67% vs. -34%, p = 0.0024) and large VLDL (-76% vs. -31%, p = 0.0016), and increasing total HDL particles (20% vs. 11%, p = 0.008) and large HDL particles (185% vs. 88%, p = 0.003). On fenofibrate therapy, 100% of those initially designated as late peakers were reclassified as early peakers; 47% of late peakers assigned to placebo were reclassified as early peakers. CONCLUSIONS: Late postprandial triglyceride responders have attenuated clearance of large VLDL particles, but they were more responsive to fenofibrate.

6 Article Impaired postprandial lipemic response in chronic kidney disease. 2016

Saland, Jeffrey M / Satlin, Lisa M / Zalsos-Johnson, Jeanna / Cremers, Serge / Ginsberg, Henry N. ·Department of Pediatrics, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Jeff.Saland@MSSM.edu. · Department of Pediatrics, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. · Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA; The Irving Institute for Clinical and Translational Research, Columbia University College of Physicians and Surgeons, New York, NY, USA. ·Kidney Int · Pubmed #27162092.

ABSTRACT: Dyslipidemia in chronic kidney disease (CKD) is usually characterized by hypertriglyceridemia. Here we studied postprandial lipemia in children and young adults to determine whether an increasing degree of CKD results in a proportional increase in triglyceride and chylomicron concentration. Secondary goals were to determine whether subnephrotic proteinuria, apolipoprotein (apo)C-III and insulin resistance modify the CKD effect. Eighteen fasting participants (mean age of 15 years, mean glomerular filtration rate (GFR) of 50 ml/min/1.73 m(2)) underwent a postprandial challenge with a high fat milkshake. Triglycerides, apoB-48, insulin, and other markers were measured before and 2, 4, 6, and 8 hours afterward. Response was assessed by the incremental area under the curve of triglycerides and of apoB-48. The primary hypothesis was tested by correlation to estimated GFR. Significantly, for every 10 ml/min/1.73 m(2) lower estimated GFR, the incremental area under the curve of triglycerides was 17% greater while that of apoB-48 was 16% greater. Univariate analyses also showed that the incremental area under the curve of triglycerides and apoB-48 were significantly associated with subnephrotic proteinuria, apoC-III, and insulin resistance. In multivariate analysis, CKD and insulin resistance were independently associated with increased area under the curve and were each linked to increased levels of apoC-III. Thus, postprandial triglyceride and chylomicron plasma excursions are increased in direct proportion to the degree of CKD. Independent effects are associated with subclinical insulin resistance and increased apoC-III is linked to both CKD and insulin resistance.

7 Article Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). 2014

Davidson, Michael H / Rosenson, Robert S / Maki, Kevin C / Nicholls, Stephen J / Ballantyne, Christie M / Mazzone, Theodore / Carlson, Dawn M / Williams, Laura A / Kelly, Maureen T / Camp, Heidi S / Lele, Aditya / Stolzenbach, James C. ·From the Department of Medicine, University of Chicago, IL (M.H.D.) · Icahn School of Medicine at Mount Sinai, New York, NY (R.S.R.) · Biofortis Clinical Research, Addison, IL (K.C.M.) · Cardiology, University of Adelaide, Adelaide, Australia (S.J.N.) · Consultant Cardiologist, Royal Adelaide Hospital, Adelaide, Australia (S.J.N.) · Section of Cardiology, Section of Atherosclerosis and Vascular Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX (C.M.B.) · the Maria and Alando J. Ballantyne, MD, Atherosclerosis Laboratory, and Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, TX (C.M.B.) · Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago (T.M.) · and Global Pharmaceutical Research and Development (D.M.C., L.A.W., M.T.K., H.S.C., J.C.S), and Data and Statistical Sciences (A.L.), AbbVie Inc, North Chicago, IL. ·Arterioscler Thromb Vasc Biol · Pubmed #24743431.

ABSTRACT: OBJECTIVE: To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) trial evaluated the effects of fenofibric acid (FA) treatment on cIMT in patients with mixed dyslipidemia on atorvastatin. APPROACH AND RESULTS: This multicenter, double-blind, placebo-controlled study was performed in patients with mixed dyslipidemia (fasting triglycerides, ≥150 mg/dL; high-density lipoprotein cholesterol, ≤45 [men] or 55 mg/dL [women]; low-density lipoprotein cholesterol, ≤100 mg/dL once and averaging ≤105 mg/dL) and a history of coronary heart disease or risk equivalent. Patients on background atorvastatin (continued on starting dose or titrated to 40 mg, if needed) were randomized to FA 135 mg or placebo. The primary end point was rate of change from baseline through week 104 of the mean posterior-wall cIMT, measured by ultrasound. In patients with controlled low-density lipoprotein cholesterol while on atorvastatin background therapy, rate of change in posterior-wall cIMT was similar with FA plus atorvastatin (-0.006 mm/y) versus atorvastatin monotherapy (0.000 mm/y; P=0.22). FA plus atorvastatin was favored (P<0.05) in 5 of 24 prespecified subgroups: age ≥60 years, history of coronary artery disease, cIMT >0.795 mm, triglycerides 170 to 235 mg/dL, and statin use at entry. Adverse events were consistent with the known safety profiles of both drugs; however, FA plus atorvastatin was associated with a greater incidence of renal-related adverse events compared with atorvastatin monotherapy (6.5% versus 0.9%). CONCLUSIONS: Compared with atorvastatin monotherapy, FA plus atorvastatin did not further decrease cIMT progression in high-risk patients with mixed dyslipidemia.

8 Article Dyslipidemia in children with chronic kidney disease. 2010

Saland, Jeffrey M / Pierce, Christopher B / Mitsnefes, Mark M / Flynn, Joseph T / Goebel, Jens / Kupferman, Juan C / Warady, Bradley A / Furth, Susan L / Anonymous500669. ·Department of Pediatrics, The Mount Sinai School of Medicine, New York, New York 10029, USA. Jeff.Saland@mssm.edu ·Kidney Int · Pubmed #20736985.

ABSTRACT: Dyslipidemia, a known risk factor for atherosclerosis, is frequent among both adults and children with chronic kidney disease. Here, we describe the prevalence and pattern of dyslipidemia from a cross-sectional analysis of 391 children aged 1-16 years, enrolled in the multicenter Chronic Kidney Disease in Children (CKiD) study, with a median glomerular filtration rate (GFR), measured by the plasma disappearance of iohexol, of 43 ml/min per 1.73 m2. Multivariate analysis was applied to adjust for age, gender, body mass index (BMI), GFR, and the urinary protein/creatinine ratio. Proteinuria was in the nephrotic range in 44 and the BMI exceeded the 95th percentile in 57 patients of this cohort. Baseline lipid analysis found a high prevalence of hypertriglyceridemia in 126, increased non-HDL-C in 62, and reduced HDL-C in 83. Overall, 177 children had dyslipidemia, of whom 79 had combined dyslipidemia. Lower GFR was associated with higher triglycerides, lower HDL-C, and higher non-HDL-C. Nephrotic-range proteinuria was significantly associated with dyslipidemia and combined dyslipidemia. Compared with children with a GFR>50, children with a GFR<30 had significantly increased odds ratios for any dyslipidemia or for combined dyslipidemia. Hence, among children with moderate chronic kidney disease, dyslipidemia is common and is associated with lower GFR, nephrotic proteinuria, and non-renal factors including age and obesity.

9 Minor Arachidonic acid as a target for treating hypertriglyceridemia reproduced by a causal network analysis and an intervention study. 2018

Yazdani, Azam / Yazdani, Akram / Bowman, Thomas A / Marotta, Francesco / Cooke, John P / Samiei, Ahmad. ·University of Texas, Health Science Center, Houston, TX, 77030, USA. a.mandana.yazdani@gmail.com. · Climax Data Pattern, Houston, TX, USA. a.mandana.yazdani@gmail.com. · Climax Data Pattern, Houston, TX, USA. · Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, 10029, USA. · Jarrow Formulas, Inc., 1824 S. Robertson Blvd, Los Angeles, CA, 90035, USA. · ReGenera Research Group for Aging Intervention, Milan, Italy. · Department of Cardiovascular Sciences, Houston Methodist, Houston, USA. · Hasso Plattner Institute, 14482, Potsdam, Germany. ·Metabolomics · Pubmed #30830364.

ABSTRACT: